Clinical Guidelines (Nursing)

Chylothorax management

  • Introduction

    Aim 

    Definition of terms

    Complications

    Diagnosis and Assessment

    Management

    Special Considerations

              Chylothorax on Butterfly Ward

    Companion Documents

    References

    Evidence Table

    Introduction 

    Chylothorax is characterised by the accumulation of chyle, a lipid and protein rich fluid within the pleural space. It often occurs due to thoracic duct trauma which can be caused by increased pressures. On Koala, this postoperative complication is often seen post cardiac surgery in patients with redivac drains insitu. Chlothorax is often characterised by a change in drainage appearance (from haemoserous to a thick, opaque and yellow texture), an increase in drainage output (particularly with the consumption of fatty foods), an increase in triglyceride levels and elevated respirations with more laboured work of breathing. Chylothorax may also be associated: tumours (lymphoma, teratomas or Wilms), chest trauma, congenital chylothorax, congenital lymphatic malformations and syndromes (such as Down Syndrome or Noonan Syndrome).

    Aim

    To guide the detection of chylothorax as well promote its management in a safe and effective manner amongst nursing and medical staff. 

    Definition of Terms 

    • Chyle: During the digestion of fatty foods, fat is broken down into chyle within the small intestine. Chyle is then taken up by lymphatic vessels and collected in the thoracic duct before draining into the blood stream. It is a lipid and protein rich fluid. It has a milky appearance and also contains albumin, lymph, emulsified fats, lymphocytes, enzymes, immunoglobulins and fat-soluble vitamins. 
    • Chylothorax: Chylothorax is characterised by the accumulation of chyle in the pleural space. The lymphatic vessels are in close proximity to blood vessels therefore chyle can leak into the pleural space if the lymphatic vessels are compromised either from damage during cardiothoracic surgery, infiltration from disease or tumors and if they are put under high pressure.
    • Thoracic Duct: One of the primary ducts of the lymphatic system which recirculates lymph into the bloodstream.
    • Monogen: A nutritionally complete, low fat and powdered feed containing whey protein. This formula is low in long chain triglycerides and high in medium chain triglycerides.
    • Medium Chain Triglyceride (MCT) Diet: A diet very low in long chain fats and supplemented with Medium Chain Triglyceride (MCT) diet. MCTs are directly absorbed into the portal circulation bypassing the lymphatic system. MCTs are essential for ensuring adequate energy intake in this highly restricted diet. 
    • Parental Nutrition (PN): is a sterile IV solution of protein, dextrose, electrolytes, vitamins, trace elements and water (nutrient) given together with a fat emulsion (lipid).
    • Somatostatin: an endogenous hormone that acts on the gastrointestinal tract.
    • Thoracic Duct Ligation: a surgical procedure performed to repair the thoracic duct leak if it fails to repair itself post conservative treatment and parenteral nutrition.

    Complications Associated with Chylothorax

    Ongoing losses of chyle can result in:

    • Infection
    • Malnutrition
    • Hypoalbuminaemia (low protein level in the blood)
    • Increased mortality
    • Immunosuppression
    • Respiratory compromise
    • Longer postoperative recovery
    • Prolonged ventilator dependence 

    Diagnosis and Assessment

    (See Figure 1)

    A chest drain (either underwater seal drain or redivac) will be inserted into the pleural space. The pleural fluid drained will be assessed for chyle using the following indicators:

    • Appearance: Chylothorax is most commonly detected by its thick, creamy like appearance in the chest drains of enterally fed patients as opposed to haemoserous pleural drainage.
    • Drainage: Sudden increase in the amount of drainage from drains, particularly in conjunction with the consumption of fatty foods. 
    • Imaging: A chest x-ray and chest ultrasound are used to confirm pleural fluid as well as show the location of and measure the size of the effusion. 
    • Drain specimen: Chylothorax is characterised by an increase in white cell count (WCC) and triglyceride levels when a drain specimen in taken.
    • Clinical symptoms: Some patients can be asymptomatic while other patients can present with shortness of breath, increased work of breathing, cough and overtime time, chest discomfort can develop.  

    Figure 1 Chylothorax

    Management

    (See Figure 2)
    Treatment is comprised of conservative and surgical interventions as listed below:

    • Conservative Treatment: is the primary and first line of treatment utilised. It is comprised of dietary modifications which include monogen feeds for infants and low fat / MCT diet for children and adolescents. Conservative treatment also includes the cessation of fatty food consumption. This form of treatment aims to slow down the production of chyle, therefore allowing the thoracic duct to repair itself. 
    • Invasive treatment: If conservative treatment fails to resolve the chylothorax (i.e. Reduce drainage, resolve drainage colour and correct bloods), invasive treatments are implemented. The first line of invasive treatment is Parental Nutrition (PN) and lipids which is administered via a central line. The patient is to remain nil by mouth whilst receiving PN. If PN fails to resolve the chylothorax, the last resort is surgical repair of the chylothorax. This includes a ligation of the thoracic duct (to repair the leak) and or surgical drainage of the pleural effusion. 
    • Please refer to special considerations below for management of Butterfly patients 

    Patient observations

    In conjunction with both conservative and invasive treatments, the following are to be adhered to:

    • Daily weights and weekly heights
    • Continue dietician involvement 
    • Monitor diet and avoidance of fatty foods
    • Strict fluid balance 
    • Hourly drain output measurements and drainage appearance documentation
    • Consider replacement of drainage losses and fluid restrictions in collaboration with medical teams (Decided on a case by case basis)
       

    Figure 2: Management of Chylothorax – The management plan below is to be followed in conjunction with the patient observations listed above. Blue - Conservative treatment; Orange – Invasive treatment; Green – Surgical Treatment. *If the patient has a cow’s milk protein intolerance, further dietician input is required in order to prescribe an alternative formula.

    fig 2 chylothorax

    Special considerations

    • Children with chylothorax going to cardiac theatre for a thoracic duct ligation
      • As soon as the patient is transferred to the operating table, any existing chest drains must be connected to suction 
      • Instrumentation for procedures must be set up prior to anaesthetic induction of the patient as there can be significant haemodynamic changes
      • In some circumstances, ward staff can prepare and ensure the availability of milk product (i.e. Double cream) from dietary kitchen. The cream is fed through the patient’s nasogastric tube by the anaesthetist on induction to facilitate the obvious leakage of chyle from the thoracic duct during surgery, therefore aiding in locating the leak 

    Chylothorax on Butterfly Ward

    For patients on Butterfly, who are typically sicker and who have diverse causes for chylothorax, approaches differ. Typically, these include fasting (with TPN), replacement of chylous pleural losses exceeding 50mL/kg/day (typically replacing 50% of the losses with 4% albumin every 4 hours), fluid restriction, ocreotide infusion and management of hypogammaglobinaemia with immunoglobulin transfusion. In the setting of diastolic cardiac dysfunction, inotropes are sometimes used. Depending on the cause, most patients eventually respond to medical management and do not require surgical interventions such as thoracic duct ligation or pleurodesis. Figure 2 is not applicable to these patients. Observations should be adhered to as described in the patient observations section above and should include continuous cardiac monitoring. 

    Medical management on Butterfly

    In terms of medical management, a trial of octreotide should be considered.

    • Octreotide is a synthetic somatostatatin analog, which is long acting. Its complete mechanism of action is unclear; however, it is thought that they may cause vasoconstriction of the splenic circulation and then a reduction in intestinal blood flow and a reduction in the production of lymphatic fluid. Please refer to Lexicomp for neonatal dosing information of octreotide.
    • Possible side effects: hyperglycaemia, hyperthyroidism, cramps, nausea, diarrhoea, renal impairment. Therefore, patients receiving these medications should have careful monitoring of their blood sugars, urine output and irritability.

    Ongoing management, special considerations and potential complications

    • Monitor for malnutrition 
    • Ensure patient and family education (i.e chylothorax and modified diet education)
    • Infection control and monitor for immunosuppression

    Companion Documents

    Links

    References

    1. Australian Medicines Handbook (AMH). Available online from: https://childrens. amh.net.au/ monographs/octreotide

    2. Ascenzi, J.A (2007). Update on Complications of Pediatric Cardiac Surgery. Critical care nursing clinics of North America. 15 (9), 361 – 369.

    3. Bulut, O et al. (2005). Treatment of chylothorax developed after Congenital Heart Disease surgery: a case report. North Clin Istanbul. 2(3): 227-230.

    4. Biewer, E.S et al. (2010). Chylothrorax after surgery on congenital heart disease in newborns and infants – Risk factors and efficacy of MCT-diet. Journal of Cardiothoracic Surgery. 5(127), 1-7.

    5. Czobor, N.R. et al. (2017). Chylothorax after paediatric cardiac surgery complications. Journal of thoracic disease. 9(8), 2466 – 2475.

    6. Chan, E.H. et al. (2005). Postoperative chylothorax after cardiothoracic surgery in children. Ann Thorac Surg. 80: 1864 – 71.

    7. Das, A & Shah, P.S. (2010). Octreotide for the treatment of chylothorax in neonates. Cochrane Database Syst Rev. 8 (9). 1-18.

    8. Haines, C. et al. (2014). Chylothorax development in infants and children in the UK. Arch Dis Children. 99 (11), 724-730. 

    9. Mery et al. (2014). Incidence and Treatment of Chylothorax After Cardiac Surgery in Children: Analysis of a Large Multi-Institution Database. The Journal of Thoracic and Cardiovascular Surgery, 47 (2), 678-686.

    10. Milonakis, M et al. (2009). Etiology and management of chylothorax following paediatric heart surgery. Journal of Cardiac Surgery. 24 (8); 369 – 373.

    11. Panthongviriyakul, C. and Bines, J.E. (2008). Post-operative chylothorax in children: An evidence-based management algorithm. Journal of Paediatrics and Child Health, 44 (12), 716-721.

    12. Tutor, J.D. (2013). Chylothorax in Infants and Children. Pediatrics, 133, 722-733.

    Evidence Table

    Chylothorax management evidence table


    Please remember to read the disclaimer.




    The development of this nursing guideline was coordinated by Charmaine Cini, RN, Platypus, and Alison Kendrick, Educator, Butterfly, approved by the Nursing Clinical Effectiveness Committee. First published July 2019.